RxDoctor Payments Data

Sandra Parawira

Nurse Practitioner · Cincinnati, OHNPI 1366725756

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,251 of the $9,570 with a category attached, or 65.3%. 13 manufacturers reported payments, led by Sanofi at 59.4% of the total. 2025 is the largest year on record at $5,924, 4.3 times the $1,366 reported in 2021. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,570in general payments, 2019–2025

Across 113 payments — averaging $84.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$6K
  • Biogen$1K
  • Novartis$918
  • TG Therapeutics, Inc.$767
  • EMD Serono, Inc.$288
  • AstraZeneca$169
  • plus $521 from 7 others

What the payments were for

  • Consulting fees$6,25165%
  • Travel & lodging$2162%
  • Food & beverage$3,10332%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,570 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$7,513
Medicare patients
57
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab58$540,742
CopaxoneGlatiramer Acetate36$210,849
AubagioTeriflunomide22$199,282
MayzentSiponimod14$133,852
GilenyaFingolimod Hcl12$119,451
TecfideraDimethyl Fumarate11$118,862
Dalfampridine ErDalfampridine54$13,051
Dimethyl Fumarate28$5,074
Baclofen194$4,092
Gabapentin164$3,175
AmantadineAmantadine Hcl18$775
Modafinil28$757
Duloxetine Hcl38$710
Pregabalin39$705
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent, Gilenya$918$253,30226 claims
SanofiAubagio$5,689$199,28222 claims
BiogenTecfidera$1,219$118,86211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →